Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture

Park, J.-H.; Kang, Kyung-Chung; Shin, Dong-Eun; Koh, Yong-kon; Son, Jae-Bong; Kim, B.-H.

doi:10.1007/s00198-013-2458-7

Cited by 35 publications

(28 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several case reports have demonstrated enhanced healing with teriparatide treatment after the patient experienced delayed fracture healing [30,31]. Teriparatide may also enhance healing of lumbar fusion [32].…”

Section: Use Of Osteoporosis Medications During Bone Healingmentioning

confidence: 96%

See 1 more Smart Citation

Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group

Silverman

Kupperman²,

Bukata³

2016

Osteoporos Int

View full text Add to dashboard Cite

show abstract

Section: Use Of Osteoporosis Medications During Bone Healingmentioning

confidence: 96%

“…Teriparatide (recombinant PTH) may enhance healing of vertebral fractures as it has been shown to prevent progression of collapse [31]. Several case reports have demonstrated enhanced healing with teriparatide treatment after the patient experienced delayed fracture healing [30,31].…”

Section: Use Of Osteoporosis Medications During Bone Healingmentioning

confidence: 98%

Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group

Silverman

Kupperman²,

Bukata³

2016

Osteoporos Int

View full text Add to dashboard Cite

show abstract

“…The low back pain with or without leg pain was the primary complaint of OVCF patients. OVCF can lead to fracture dislocation of the spine causing spinal instability and spinal cord damage 5 . OVCF affects patients' quality of life.…”

Section: Introductionmentioning

confidence: 99%

Percutaneous Vertebroplasty with Side‐Opening Cannula or Front‐Opening Cannula in the Treatment of Kummell Disease?

Ping

Zeng

et al. 2020

Orthopaedic Surgery

View full text Add to dashboard Cite

Objective To explore the effect of bone cement distribution, cement leakage, and clinical outcomes with side‐opening cannula for bone cement injection in percutaneous vertebroplasty (PVP) in treatment of Kummell disease. Methods A prospective study of patients with Kummell disease undergoing PVP was conducted from April 2012 to September 2017. In total, 43 patients (11 males, 32 females) with Kummell disease who received bilateral PVP were included in the study. The patients were divided into front‐opening cannulas (FOC) group with front‐opening cannulas and side‐opening cannulas (SOC) group with side‐opening cannulas. All patients were followed up for 6 months. The patient general information such as gender, age, bone density, compression ratio, operative time, and location of fracture vertebrae were recorded. Visual analogue scale (VAS), Oswestry Disability Index (ODI), bone cement distribution, radiation exposure time, bone cement leakage rate and vertebral height, and kyphosis angle were measured and compared for two groups before surgery, 1 day and 6 months after surgery. Results A total of 43 patients were enrolled, including 11 males and 32 females, aged 61–84 years. The bone density (T value) was 2.5 ± 0.6 in FOC group and 2.4 ± 0.6 in SOC group (P > 0.05). The compression ratio and operative time were 36.1% ± 13.0%, 39.3 ± 7.9 min in FOC group and 35.2% ± 13.7%, 40.0 ± 10.7 min in SOC group (P > 0.05). There was no significance between FOC and SOC groups in the location of fracture vertebrae. All patients underwent at least 6 months of follow‐up. At 6 months postoperatively, the VAS and ODI were significantly higher in the FOC group (3.0 ± 0.8, 35.7% ± 2.1%) than in the SOC group (1.3 ± 0.4, 18.6% ± 2.4%) (P < 0.05). The cement leakage rate of the SOC group was 4.8%, which was lower than that of the FOC group (31.8%, P < 0.05), and the bone cement distribution ratio was higher than that of the FOC group (63.1% ± 7.9% vs 40.5% ± 8.6%, P < 0.05). At 6 months after operation, the height of the anterior and posterior vertebral bodies of the patients in the SOC group restored better than the FOC group (anterior SOC: FOC 5.1 ± 0.5 mm vs 4.5 ± 0.5 mm; posterior SOC: FOC 0.6 ± 0.1 mm vs 0.3 ± 0.1 mm, P < 0.05), and the kyphosis correction was more obvious than patients in FOC group (SOC: FOC 8.5° ± 1.4° vs 4.6° ± 0.8°, P < 0.05). Conclusion Percutaneous vertebroplasty with side‐opening cannula is safe and effective in avoiding bone cement leakage, improving bone cement distribution, and restoring vertebral height.

show abstract

“… 5 Teriparatide involves a direct mechanism that stimulates bone formation and improves bone strength faster than other anti-resorptive osteoporosis medications. 4 , 6 , 7 , 8 , 9 …”

Section: Introductionmentioning

confidence: 99%

At Least One Cyclic Teriparatide Administration Can Be Helpful to Delay Initial Onset of a New Osteoporotic Vertebral Compression Fracture

et al. 2014

View full text Add to dashboard Cite

PurposeTeriparatide markedly increases bone formation and strength, while reducing the incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors' country does not cover these expenses. This retrospective cohort study compared the therapeutic effects of teriparatide on the initial onset of a new OVCF after treatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M).Materials and MethodsFrom May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272).ResultsThe group with the teriparatide duration of LT3M showed significantly less development of an initial OVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosis significantly affected multiple regression analysis results (p<0.05). Survival analysis of first new-onset OVCFs demonstrated a significantly better survival rate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006).ConclusionAt least one cyclic teriparatide administration is recommended to provide a protective effect against the initial onset of a new OVCF for up to one year after therapy.

show abstract

Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture

Abstract: In female patients with single-level osteoporotic VCF at the thoracolumbar junction, short-term teriparatide treatment did not prevent but did decrease the progression of fractured vertebral body collapse.

Cited by 35 publications

References 22 publications

Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group

Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group

Percutaneous Vertebroplasty with Side‐Opening Cannula or Front‐Opening Cannula in the Treatment of Kummell Disease?

At Least One Cyclic Teriparatide Administration Can Be Helpful to Delay Initial Onset of a New Osteoporotic Vertebral Compression Fracture

Contact Info

Product

Resources

About